NPR's
"Shots" blog published on one of the drug trials thought by the Food
and Drug Administration in its certification of the antiretroviral medication
Truvada for pre-exposure prophylaxis (PrEP) to avoid HIV among people at risk
of contracting the virus, which generally "was done at the Oswaldo Cruz
Foundation Research Institute, also referred to as Fiocruz, in Rio de
Janeiro."
"Brenda
Hoagland, the medical organizer as to the study at Fiocruz, says the trial
confirmed that is actually Truvada was safe and offered a top level of safety
against HIV when consumed daily," but "she includes that Truvada is
certainly not a magic bullet," in accordance with the blog.
"It
is really not for everybody," she replied, posting, "It's for all
those people who really have a risk," an example would be sex workers or
someone whose companion is HIV-positive, the blog notes. "In general the
AIDS epidemic in Brazil remains concentrated among prostitutes, intravenous
usage and gay men," in accordance with the blog.
No comments:
Post a Comment